66 related articles for article (PubMed ID: 25630940)
1. Human monocyte-derived suppressor cells control graft-versus-host disease by inducing regulatory forkhead box protein 3-positive CD8+ T lymphocytes.
Janikashvili N; Trad M; Gautheron A; Samson M; Lamarthée B; Bonnefoy F; Lemaire-Ewing S; Ciudad M; Rekhviashvili K; Seaphanh F; Gaugler B; Perruche S; Bateman A; Martin L; Audia S; Saas P; Larmonier N; Bonnotte B
J Allergy Clin Immunol; 2015 Jun; 135(6):1614-24.e4. PubMed ID: 25630940
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo.
Horwitz DA; Pan S; Ou JN; Wang J; Chen M; Gray JD; Zheng SG
Clin Immunol; 2013 Dec; 149(3):450-63. PubMed ID: 24211847
[TBL] [Abstract][Full Text] [Related]
3. Human iPSC-derived CD4
Yano H; Koga K; Sato T; Shinohara T; Iriguchi S; Matsuda A; Nakazono K; Shioiri M; Miyake Y; Kassai Y; Kiyoi H; Kaneko S
Cell Stem Cell; 2024 Jun; 31(6):795-802.e6. PubMed ID: 38848686
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of xenoantigen‑stimulated T cell receptor Vβ‑restricted human regulatory T cells prevents porcine islet xenograft rejection in humanized mice.
Jin X; Hu M; Gong L; Li H; Wang Y; Ji M; Li H
Mol Med Rep; 2018 Nov; 18(5):4457-4467. PubMed ID: 30221725
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo.
Parmar S; Liu X; Najjar A; Shah N; Yang H; Yvon E; Rezvani K; McNiece I; Zweidler-McKay P; Miller L; Wolpe S; Blazar BR; Shpall EJ
Blood; 2015 Feb; 125(9):1502-6. PubMed ID: 25428215
[TBL] [Abstract][Full Text] [Related]
6. Glutamine supplementation improves the activity and immunosuppressive action of induced regulatory T cells in vitro and in vivo.
Zhang L; Xu Z; Li Y; Wu KJ; Yu C; Zhu W; Sun DL; Zhu L; Zhou J
Transpl Immunol; 2024 Jun; 84():102044. PubMed ID: 38663757
[TBL] [Abstract][Full Text] [Related]
7. Enforced gut homing of murine regulatory T cells reduces early graft-versus-host disease severity.
Larson JH; Jin S; Loschi M; Bolivar Wagers S; Thangavelu G; Zaiken MC; McDonald-Hyman C; Saha A; Aguilar EG; Koehn B; Osborn MJ; Panoskaltsis-Mortari A; Macdonald KPA; Hill GR; Murphy WJ; Serody JS; Maillard I; Kean LS; Kim SV; Littman DR; Blazar BR
Am J Transplant; 2023 Aug; 23(8):1102-1115. PubMed ID: 36878433
[TBL] [Abstract][Full Text] [Related]
8. CD8-positive lymphocytes in graft-versus-host disease of humanized NOD.Cg-Prkdc(scid)Il2rg(tm1Wjl)/SzJ mice.
Laing ST; Griffey SM; Moreno ME; Stoddart CA
J Comp Pathol; 2015; 152(2-3):238-42. PubMed ID: 25670669
[TBL] [Abstract][Full Text] [Related]
9. Co-transplantation of human fetal thymus, bone and CD34(+) cells into young adult immunodeficient NOD/SCID IL2Rγ(null) mice optimizes humanized mice that mount adaptive antibody responses.
Chung YS; Son JK; Choi B; Joo SY; Lee YS; Park JB; Moon H; Kim TJ; Kim SH; Hong S; Chang J; Kang MS; Kim SJ
Clin Immunol; 2015 Apr; 157(2):156-65. PubMed ID: 25725428
[TBL] [Abstract][Full Text] [Related]
10. Staphylococcus aureus Infection in Humanized Mice: A New Model to Study Pathogenicity Associated With Human Immune Response.
Knop J; Hanses F; Leist T; Archin NM; Buchholz S; Gläsner J; Gessner A; Wege AK
J Infect Dis; 2015 Aug; 212(3):435-44. PubMed ID: 25657257
[TBL] [Abstract][Full Text] [Related]
11. Rapid memory T-cell reconstitution recapitulating CD45RA-depleted haploidentical transplant graft content in patients with hematologic malignancies.
Triplett BM; Shook DR; Eldridge P; Li Y; Kang G; Dallas M; Hartford C; Srinivasan A; Chan WK; Suwannasaen D; Inaba H; Merchant TE; Pui CH; Leung W
Bone Marrow Transplant; 2015 Jul; 50(7):968-77. PubMed ID: 25665048
[TBL] [Abstract][Full Text] [Related]
12. CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response.
Betts BC; Sagatys EM; Veerapathran A; Lloyd MC; Beato F; Lawrence HR; Yue B; Kim J; Sebti SM; Anasetti C; Pidala J
J Leukoc Biol; 2015 Apr; 97(4):807-19. PubMed ID: 25663681
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficiency of human immune system reconstitution in NSG mice and NSG mice containing a human HLA.A2 transgene using hematopoietic stem cells purified from different sources.
Patton J; Vuyyuru R; Siglin A; Root M; Manser T
J Immunol Methods; 2015 Jul; 422():13-21. PubMed ID: 25776756
[TBL] [Abstract][Full Text] [Related]
14. Human Blood and Mucosal Regulatory T Cells Express Activation Markers and Inhibitory Receptors in Inflammatory Bowel Disease.
Lord JD; Shows DM; Chen J; Thirlby RC
PLoS One; 2015; 10(8):e0136485. PubMed ID: 26305224
[TBL] [Abstract][Full Text] [Related]
15. Humanized Chronic Graft-versus-Host Disease in NOD-SCID il2rγ-/- (NSG) Mice with G-CSF-Mobilized Peripheral Blood Mononuclear Cells following Cyclophosphamide and Total Body Irradiation.
Fujii H; Luo ZJ; Kim HJ; Newbigging S; Gassas A; Keating A; Egeler RM
PLoS One; 2015; 10(7):e0133216. PubMed ID: 26176698
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T-Cell Development in the Human Thymus.
Caramalho Í; Nunes-Cabaço H; Foxall RB; Sousa AE
Front Immunol; 2015; 6():395. PubMed ID: 26284077
[TBL] [Abstract][Full Text] [Related]
17. Efficiency of human monocyte-derived suppressor cell-based treatment in graft-versus-host disease prevention while preserving graft-versus-leukemia effect.
Janikashvili N; Gérard C; Thébault M; Brazdova A; Boibessot C; Cladière C; Ciudad M; Greigert H; Ouandji S; Ghesquière T; Samson M; Audia S; Saas P; Bonnotte B
Oncoimmunology; 2021 Feb; 10(1):1880046. PubMed ID: 33659098
[TBL] [Abstract][Full Text] [Related]
18. Innate immune cellular therapeutics in transplantation.
Ott LC; Cuenca AG
Front Transplant; 2023; 2():. PubMed ID: 37994308
[TBL] [Abstract][Full Text] [Related]
19. Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment.
Hess NJ; Kink JA; Hematti P
Front Immunol; 2023; 14():1143381. PubMed ID: 37063900
[TBL] [Abstract][Full Text] [Related]
20. Human monocyte-derived suppressive cells (HuMoSC) for cell therapy in giant cell arteritis.
Samson M; Genet C; Corbera-Bellalta M; Greigert H; Espígol-Frigolé G; Gérard C; Cladière C; Alba-Rovira R; Ciudad M; Gabrielle PH; Creuzot-Garcher C; Tarris G; Martin L; Saas P; Audia S; Bonnotte B; Cid MC
Front Immunol; 2023; 14():1137794. PubMed ID: 36895571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
